Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Management of invasive group A streptococcal infections

Invasive group A streptococcal disease in children includes deep soft tissue infection, bacteraemia, bacteraemic pneumonia, meningitis and osteomyelitis

Research

Echocardiographic screening for rheumatic heart disease in high and low risk Australian children

We aimed to establish the prevalence of RHD in high-risk Indigenous Australian children using these criteria and to compare the findings with a group of...

Research

Echocardiographic screening in a resource poor setting: Borderline rheumatic heart disease could be a normal variant

Cross-sectional observational study across ten primary schools in Fiji in school children aged 5-14 years.

Research

Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012

This paper examines the use of a new antibiotic to treat diarrhoea cause by Cryptosporidium infection in Australian Indigenous children.

Research

Extensive Diversity of Streptococcus pyogenes in a Remote Human Population Reflects Global-Scale Transmission Rather than Localised Diversification

The Indigenous population of the Northern Territory of Australia (NT) suffers from a very high burden of Streptococcus pyogenes disease, including cardiac...

Research

Post-infectious group A streptococcal autoimmune syndromes and the heart

ARF is a classical example of an autoimmune syndrome and is of particular immunological interest because it follows a known antecedent infection with group A...

Research

Primary prevention of rheumatic fever in the 21st century: evaluation of a national programme

Population-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand

Research

An economic case for a vaccine to prevent group A streptococcus skin infections

A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability

Research

Development of an opsonophagocytic killing assay for group a streptococcus

This Group A Streptococcus OPKA assay has the potential to provide a robust and reproducible platform to accelerate GAS vaccine development